230 related articles for article (PubMed ID: 18812048)
1. Estimating the market for tuberculosis drugs in industrialized and developing nations.
Schwalbe NR; Wells WA; Geaneotes AP; Forcellina A; Lee MG; Dicola L; Ignatius HR; Walker CL; Raafat T; Patel N
Int J Tuberc Lung Dis; 2008 Oct; 12(10):1173-81. PubMed ID: 18812048
[TBL] [Abstract][Full Text] [Related]
2. The Global TB Drug Facility: innovative global procurement.
Kumaresan J; Smith I; Arnold V; Evans P
Int J Tuberc Lung Dis; 2004 Jan; 8(1):130-8. PubMed ID: 14974756
[TBL] [Abstract][Full Text] [Related]
3. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
Catalani E
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S289-91; discussion S317-21. PubMed ID: 10593707
[TBL] [Abstract][Full Text] [Related]
4. Estimate of the global market for rifampicin-containing fixed-dose combination tablets.
Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708
[TBL] [Abstract][Full Text] [Related]
5. Treatment of extensively drug-resistant tuberculosis and role of the pharmacist.
Mitrzyk BM
Pharmacotherapy; 2008 Oct; 28(10):1243-54. PubMed ID: 18823220
[TBL] [Abstract][Full Text] [Related]
6. TB drug prices slashed for poor countries.
Hagmann M
Bull World Health Organ; 2001; 79(9):904-5. PubMed ID: 11584747
[No Abstract] [Full Text] [Related]
7. Opportunities for overcoming tuberculosis: new treatment regimens.
Freire MC
World Hosp Health Serv; 2006; 42(1):34-7. PubMed ID: 16669375
[TBL] [Abstract][Full Text] [Related]
8. Modeling the epidemiology and economics of directly observed therapy in Baltimore.
Chaulk CP; Friedman M; Dunning R
Int J Tuberc Lung Dis; 2000 Mar; 4(3):201-7. PubMed ID: 10751064
[TBL] [Abstract][Full Text] [Related]
9. Viewpoint: do we have enough data to estimate the current burden of tuberculosis? The example of Bangladesh.
Begum V; van der Werf MJ; Becx-Bleumink M; Borgdorff MW
Trop Med Int Health; 2007 Mar; 12(3):317-22. PubMed ID: 17313503
[TBL] [Abstract][Full Text] [Related]
10. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
[TBL] [Abstract][Full Text] [Related]
11. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.
Danzon PM; Wang YR; Wang L
Health Econ; 2005 Mar; 14(3):269-92. PubMed ID: 15386651
[TBL] [Abstract][Full Text] [Related]
12. Global perspectives on vaccine financing.
Berman S; Giffin RB
Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis in Thailand: epidemiology and program performance, 2001-2005.
Jittimanee S; Vorasingha J; Mad-asin W; Nateniyom S; Rienthong S; Varma JK
Int J Infect Dis; 2009 Jul; 13(4):436-42. PubMed ID: 19013094
[TBL] [Abstract][Full Text] [Related]
14. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of different subgroups of smear-positive retreatment patients under RNTCP in rural West Bengal, India.
Mukherjee A; Sarkar A; Saha I; Biswas B; Bhattacharyya PS
Rural Remote Health; 2009; 9(1):926. PubMed ID: 19260766
[TBL] [Abstract][Full Text] [Related]
16. Current status and future prospects for new therapies for pulmonary tuberculosis.
de Souza MV
Curr Opin Pulm Med; 2006 May; 12(3):167-71. PubMed ID: 16582670
[TBL] [Abstract][Full Text] [Related]
17. Distribution of road traffic deaths by road user group: a global comparison.
Naci H; Chisholm D; Baker TD
Inj Prev; 2009 Feb; 15(1):55-9. PubMed ID: 19190278
[TBL] [Abstract][Full Text] [Related]
18. Paving the way for the introduction of new vaccines into developing countries.
Chabalgoity JA
Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986
[TBL] [Abstract][Full Text] [Related]
19. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
Smart A; Martin P
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of pulmonary tuberculosis].
Boldú J; Cebollero P; Abu J; De Prado A
An Sist Sanit Navar; 2007; 30 Suppl 2():99-115. PubMed ID: 17898831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
